Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Inulin on Satiety and Food Intake

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01025375
First received: December 2, 2009
Last updated: August 29, 2012
Last verified: August 2012

December 2, 2009
August 29, 2012
January 2009
February 2010   (final data collection date for primary outcome measure)
food intake [ Time Frame: on testday 0 and 13 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01025375 on ClinicalTrials.gov Archive Site
  • appetite profile ratings [ Time Frame: on test day 0, 8 and 13 (at 16 time points) ] [ Designated as safety issue: No ]
  • satiety hormones (GLP-1 and PYY) [ Time Frame: on test day 0 and 13 (at 9 time points ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Effects of Inulin on Satiety and Food Intake
Effects of Inulin on Satiety and Food Intake

To assess the effect of inulin on appetite profile ratings, food intake and satiety hormones.

Based upon a slower digestion and the fermentation in the intestinal tract, food containing soluble dietary fibres, such as inulin, is hypothesized to be more satiating, and to limit energy intake, in humans. Does supplementation of inulin (at 2 dosages) versus placebo over 13 consecutive days in normal to overweight men and women, lead to an increase in satiety, a reduction in food intake and stronger postprandial increases in GLP-1 and PYY?

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Obesity
  • Dietary Supplement: inulin
    10gram/day inulin for 13-day treatment
    Other Name: oligofructose
  • Dietary Supplement: inulin
    16gram/day inulin for 13-day treatment
    Other Name: oligofructose
  • Dietary Supplement: placebo
    16gram/day maltodextrin (placebo) for 13-day treatment
    Other Name: maltodextrin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age between 18 and 60 years
  • BMI between 23 and 28 kg/m2
  • dietary unrestraint (TFEQ: F1<9)

Exclusion Criteria:

  • age under 18 and above 60 years
  • BMI under 23 and above 28 kg/m2
  • dietary restraint (TFEQ: F1>9)
  • use of medication
  • pregnant or breastfeeding
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01025375
HumBio_Westerterp08_2
Yes
Maastricht University Medical Center
Maastricht University Medical Center
Not Provided
Principal Investigator: Klaas R Westerterp, Prof NUTRIM
Maastricht University Medical Center
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP